RespireRx Pharmaceuticals Inc (fka RSPI)

[corwatcher]

Neuro, help me understand something. It seems that there are those on this board that continue to say there is still a dose limitation on CX717, but also seem to believe that Cortex is in the process of filing a new protocol for another ADHD trial. How and why would Cortex file for a new trial if they could only expect to run the trial with the low dose limitation that was put into place last year (they didn’t want to pursue any trials with the lose dose limitation in place at that time, why now)? The fact that they are putting together a new proposal for an ADHD trial should be evidence that the prior limitation has been lifted. Wouldn’t they be wasting their time and the FDA if they are knowingly submitting a proposal for a trial or trials that ask for dosing that is currently NOT allowed? What am it missing?